INTERVIEW: Faron Chairman Discusses Bettering Pharma's Reputation And Having No Regrets
Executive Summary
Frank Armstrong is an industry veteran with no intention of slowing down. Over his 30-year career, he has held CEO roles with five biotechnology companies and led medical science and innovation at Merck Serono, and was previously executive vice president of product development at Bayer and senior vice president of medical research and communications at Zeneca. He now chairs the Finnish pharma company Faron's board and has high hopes for its drug Traumakine.
You may also be interested in...
Faron Appoints Medical Director For 2016
Finnish drug development company Faron Pharmacetuicals Ltd. has named Dr. Matti Karvonen medical director.
Video Interview: Faron Crosses Finnish Line To Increase Global Footprint
Having raised £10m floating on London's Alternative Investment Market (AIM) in November 2015, Finland's Faron Pharmaceuticals is planning to establish a more prominent international presence over the next year and a half. President and CEO Dr. Markku Jalkanen explains to Mike Ward, Informa Pharma Insights' global director of content, why the company chose to float in London and how it intends to use the funds to break out of Finland and build a larger global footprint.
Faron Pharmaceuticals floats as lead product enters Phase III
Turku, Finland-based Faron Pharmaceuticals has floated on the London Stock Exchange's Alternative Investment Market (AIM), raising £10m to fund a Phase III trial for its lead product, orphan drug Traumakine.